Trials / Completed
CompletedNCT00552227
Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus
The Effect of Protein Kinase C (PKC) β Specific Inhibitor on Oxidant Stress in Patient With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Chromaderm, Inc. · Industry
- Sex
- All
- Age
- 35 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether ruboxistaurin can reduce blood vessel inflammation associated with diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ruboxistaurin | oral 32 mg daily |
| OTHER | placebo | placebo |
Timeline
- Start date
- 2002-09-01
- Completion
- 2005-07-01
- First posted
- 2007-11-01
- Last updated
- 2016-07-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00552227. Inclusion in this directory is not an endorsement.